Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-27T12:56:58.440Z Has data issue: false hasContentIssue false
  • English
  • Français

The COVID-19 hospitalization metric in the pre- and postvaccination eras as a measure of pandemic severity: A retrospective, nationwide cohort study

Part of: SARS-CoV-2/COVID-19

Published online by Cambridge University Press:  11 January 2022

Nathanael R. Fillmore Open the ORCID record for Nathanael R. Fillmore [Opens in a new window] ,
Jennifer La ,
Chunlei Zheng ,
Shira Doron ,
Nhan V. Do ,
Paul A. Monach  and
Westyn Branch-Elliman Open the ORCID record for Westyn Branch-Elliman [Opens in a new window]
Nathanael R. Fillmore
Affiliation:
Department of Medicine, Veterans’ Affairs (VA) Boston Healthcare System, Boston, Massachusetts Dana Farber Cancer Institute, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
Jennifer La
Affiliation:
VA Boston Cooperative Studies Program, Boston, Massachusetts
Chunlei Zheng
Affiliation:
VA Boston Cooperative Studies Program, Boston, Massachusetts
Shira Doron
Affiliation:
Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts
Nhan V. Do
Affiliation:
Department of Medicine, Veterans’ Affairs (VA) Boston Healthcare System, Boston, Massachusetts VA Boston Cooperative Studies Program, Boston, Massachusetts Boston University School of Medicine, Boston, Massachusetts
Paul A. Monach
Affiliation:
Department of Medicine, Veterans’ Affairs (VA) Boston Healthcare System, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts VA Boston Cooperative Studies Program, Boston, Massachusetts
Westyn Branch-Elliman*
Affiliation:
Department of Medicine, Veterans’ Affairs (VA) Boston Healthcare System, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts VA Boston Cooperative Studies Program, Boston, Massachusetts VA Boston Center for Healthcare Organization and Implementation Research, Boston, Massachusetts
*
Author for correspondence: Westyn Branch-Elliman, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Coronavirus disease 2019 (COVID-19) hospitalization definitions do not include a disease severity assessment. Thus, we sought to identify a simple and objective mechanism for identifying hospitalized severe cases and to measure the impact of vaccination on trends.

Methods:

All admissions to a Veterans’ Affairs (VA) hospital, where routine inpatient screening is recommended, between March 1, 2020, and November 22, 2021, with laboratory-confirmed severe acute respiratory coronavirus virus 2 (SARS-CoV-2) were included. Moderate-to-severe COVID-19 was defined as any oxygen supplementation or any oxygen saturation (SpO2) <94% between 1 day before and 2 weeks after the positive SARS-CoV-2 test. Admissions with moderate-to-severe disease were divided by the total number of admissions, and the proportion of admissions with moderate-to-severe COVID-19 was modelled using a penalized spline in a Poisson regression and stratified by vaccination status. Dexamethasone receipt and its correlation with moderate-to-severe cases was also assessed.

Results:

Among 67,025 admissions with SARS-CoV-2, the proportion with hypoxemia or supplemental oxygen fell from 64% prior to vaccine availability to 56% by November 2021, driven in part by lower rates in vaccinated patients (vaccinated, 52% versus unvaccinated, 58%). The proportion of cases of moderate-to-severe disease identified using SpO2 levels and oxygen supplementation was highly correlated with dexamethasone receipt (correlation coefficient, 0.95), and increased after July 1, 2021, concurrent with δ (delta) variant predominance.

Conclusions:

A simple and objective definition of COVID-19 hospitalizations using SpO2 levels and oxygen supplementation can be used to track pandemic severity. This metric could be used to identify risk factors for severe breakthrough infections, to guide clinical treatment algorithms, and to detect trends in changes in vaccine effectiveness over time and against new variants.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 12 , December 2022 , pp. 1767 - 1772
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

a,b

Authors of equal contribution.

References

Coronavirus disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html#:∼:text=About%20COVID%2DNET-,Coronavirus%20Disease%202019%20(COVID%2D19)%2DAssociated%20Hospitalization%20Surveillance%20Network,care%20hospitals%20in%2014%20states. Published 2020. Accessed March 18, 2022.Google Scholar
Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC—United States, January. Centers for Disease Control and Prevention website. https://www.cdc.gov/mmwr/volumes/70/wr/mm7021e3.html. Accessed March 18, 2022.Google Scholar
Oliver, SE, Gargano, JW, Marin, M, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. Morb Mortal Wkly Rep 2020;69:1922.CrossRefGoogle ScholarPubMed
Allen, H, Vusirikala, A, Flannagan, J, et al. Increased household transmission of COVID-19 cases associated with SARS-CoV-2 variant of concern B. 1.617. 2: a national case–control study. Lancet Reg Health Eur 2022;12:100252.Google Scholar
COVID-19 Shared Data Resource (2020). VA Healthcare System website.   https://www.va.gov. Published 2020. Accessed December 7, 2021.Google Scholar
Gelman, M. VA Guidebook on COVID-19 Testing v 1.2 27 (2021). Veterans’ Affairs Health website. https://dvagov.sharepoint.com/sites/VACOVHAPublicHealth/HCI/Screening%20Diagnosis%20%20Treatment/Forms/AllItems.aspx?RootFolder=%2Fsites%2FVACOVHAPublicHealth%2FHCI%2FScreening%20Diagnosis%20%20Treatment%2FTesting&FolderCTID=0x012000EE9E64DFF6DF2E4C97D13B1AE9C60CCA. Updated January 21, 2022. Accessed March 18, 2022.Google Scholar
Chronic Conditions Data Warehouse. Centers for Medicare and Medicaid Services website. https://www2.ccwdata.org/web/guest/condition-categories. Published 2021. Accessed November 30, 2021.Google Scholar
Clinical spectrum of SARS-CoV-2 infection. National Institutes of Health website. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Updated September 3, 2021. Accessed September 6, 2021.Google Scholar
Therapeutic management of hospitalized adults with COVID-19. National Institutes of Health website. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/. Accessed September 17, 2021.Google Scholar
Asundi, A, Resnik, J, Benedict, PA, Shin, M, Rani Elwy, A, Branch-Elliman, W. How are emerging data translated into clinical practice? A mixed methods investigation of coronavirus disease 2019 institutional treatment protocols. Open Forum Infect Dis 2021;8(4):ofab072.CrossRefGoogle ScholarPubMed
Ohl, ME, Miller, DR, Lund, BC, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. JAMA Netw Open 2021;4:e2114741.Google ScholarPubMed
COVID-19 vaccine breakthrough case investigation and reporting. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/php/hd-breakthrough.html. Published 2021. Accessed March 18, 2022.Google Scholar
Lopez Bernal, J, Andrews, N, Gower, C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021;385:585–594.Google ScholarPubMed
Bar-On, YM, Goldberg, Y, Mandel, M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med 2021;385:1393–1400.CrossRefGoogle ScholarPubMed
Branch-Elliman, W, Ferguson, R, Doros, G, et al. Subcutaneous sarilumab for the treatment of hospitalized patients with severe COVID-19 disease: a pragmatic, embedded, randomized controlled trial. PLoS One 2022;17:e0263591.CrossRefGoogle Scholar
Calderwood, MS, Deloney, VM, Anderson, DJ, et al. Policies and practices of SHEA Research Network hospitals during the COVID-19 pandemic. Infect Control Hosp Epidemiol 2020;41:1127–1135.CrossRefGoogle Scholar
Webb, NE, Osburn, TS. Characteristics of hospitalized children positive for SARS-CoV-2: experience of a large center. Hosp Pediatr 2021;11:e133–e141.Google ScholarPubMed
Kushner, LE, Schroeder, AR, Kim, J, Mathew, R. “For COVID” or “With COVID”: classification of SARS-CoV-2 hospitalizations in children. Hosp Pediatr 2021;11:e151–e156.CrossRefGoogle ScholarPubMed
COVID-19 Treatment Guidelines. National Institutes of Health website. https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/. Updated October 27, 2021. Accessed November 30, 2021.Google Scholar
Supplementary material: File

Fillmore et al. supplementary material

Fillmore et al. supplementary material

Download Fillmore et al. supplementary material(File)
File 1.6 MB